Modeled Health Economic Impact of a Hypothetical Certolizumab Pegol Risk-Sharing Scheme for Patients with Moderate-to-Severe Rheumatoid Arthritis in Finland

被引：0
|
作者：
Erkki Soini
Christian Asseburg
Maarit Taiha
Kari Puolakka
Oana Purcaru
Riitta Luosujärvi
机构：
[1] ESiOR Oy,Department of Rheumatology
[2] UCB Pharma Oy Finland,undefined
[3] South Karelia Central Hospital,undefined
[4] UCB Pharma S.A. Belgium,undefined
[5] Helsinki University Hospital,undefined
来源：
Advances in Therapy | 2017年 / 34卷
关键词：
Biological therapies; Certolizumab pegol; Disease-modifying antirheumatic drugs; Health economics; Health policies; Rheumatoid arthritis; Rheumatology;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2316 / 2332
页数：16
相关论文
共 33 条
  • [1] Modeled Health Economic Impact of a Hypothetical Certolizumab Pegol Risk-Sharing Scheme for Patients with Moderate-to-Severe Rheumatoid Arthritis in Finland
    Soini, Erkki
    Asseburg, Christian
    Taiha, Maarit
    Puolakka, Kari
    Purcaru, Oana
    Luosujarvi, Riitta
    [J]. ADVANCES IN THERAPY, 2017, 34 (10) : 2316 - 2332
  • [2] Certolizumab pegol in a heterogeneous population of patients with moderate-to-severe rheumatoid arthritis
    Soriano, Enrique R.
    Dellepiane, Analia
    Salvatierra, Gabriela
    Alejandro Benitez, Cristian
    Garcia Salinas, Rodrigo
    Baruzzo, Carlos
    [J]. FUTURE SCIENCE OA, 2018, 4 (04):
  • [3] BUDGET IMPACT ANALYSIS OF CERTOLIZUMAB PEGOL IN THE MANAGEMENT OF PATIENTS WITH MODERATE-TO-SEVERE ACTIVE RHEUMATOID ARTHRITIS IN GREECE
    Tzanetakos, C.
    Maniadakis, N.
    Kourlaba, G.
    Tzioufas, A.
    Goules, A.
    Theodoratou, T.
    Christou, P.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : 375 - 375
  • [4] Experience of a Performance-Based Risk-Sharing Arrangement for the Treatment of Rheumatoid Arthritis With Certolizumab Pegol
    Di Giuseppe, Luis A.
    Buela, Gabriela
    Zacariaz Hereter, Johana B.
    Terrasa, Sergio A.
    Garfi, Leonardo G.
    Soriano, Enrique R.
    [J]. VALUE IN HEALTH REGIONAL ISSUES, 2020, 21 : 201 - 204
  • [5] Experience of a Performance-Based Risk-Sharing Arrangement for the Treatment of Rheumatoid Arthritis With Certolizumab Pegol
    Buela, Gabriela
    Di Giuseppe, L. A.
    Zacariaz Hereter, J. B.
    Adrian Terrasa, Sergio
    Garfi, L. A.
    Soriano, E. R.
    [J]. INTERNATIONAL JOURNAL OF INTEGRATED CARE, 2022, 22
  • [6] Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis in Greece
    C. Tzanetakos
    A. Tzioufas
    A. Goules
    G. Kourlaba
    T. Theodoratou
    P. Christou
    N. Maniadakis
    [J]. Rheumatology International, 2017, 37 : 1441 - 1452
  • [7] Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis in Greece
    Tzanetakos, C.
    Tzioufas, A.
    Goules, A.
    Kourlaba, G.
    Theodoratou, T.
    Christou, P.
    Maniadakis, N.
    [J]. RHEUMATOLOGY INTERNATIONAL, 2017, 37 (09) : 1441 - 1452
  • [8] COST-EFFECTIVENESS AND BUDGET IMPACT OF CERTOLIZUMAB PEGOL AGAINST A MIX OF TREATMENTS IN AN OUTCOMES-BASED RISK-SHARING SCHEME IN FINLAND
    Asseburg, C.
    Soini, E. J.
    Taiha, M.
    [J]. VALUE IN HEALTH, 2012, 15 (07) : A454 - A454
  • [9] COST-UTILITY AND BUDGET IMPACT ANALYSIS OF CERTOLIZUMAB PEGOL PLUS METHOTREXATE FOR THE TREATMENT OF MODERATE-TO-SEVERE ACTIVE RHEUMATOID ARTHRITIS IN GREECE
    Maniadakis, N.
    Boumpas, D.
    Kourlaba, G.
    Christou, P.
    Anargiros, I
    Smets, E.
    Purcaru, O.
    [J]. VALUE IN HEALTH, 2011, 14 (07) : A310 - A310
  • [10] COST-UTILITY ANALYSIS OF CERTOLIZUMAB PEGOL PLUS METHOTREXATE FOR THE TREATMENT OF MODERATE-TO-SEVERE ACTIVE RHEUMATOID ARTHRITIS IN GREECE
    Tzanetakos, C.
    Maniadakis, N.
    Kourlaba, G.
    Tzioufas, A.
    Goules, A.
    Theodoratou, T.
    Christou, P.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A382 - A382
1234